Draig Therapeutics raised $65 million in an oversubscribed Series B to move DT-101, its AMPA receptor potentiator, through Phase III programs in major depressive disorder. The Cardiff University spinout said it has ongoing Phase II studies and will use the funding to accelerate the neurocircuit-focused pipeline, with investors highlighting rapid execution from stealth through initiation of later-stage trials.